2021
DOI: 10.1016/j.ijpharm.2021.120956
|View full text |Cite
|
Sign up to set email alerts
|

Health care-associated infections: Controlled delivery of cationic antiseptics from polymeric excipients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
5
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(5 citation statements)
references
References 152 publications
0
5
0
Order By: Relevance
“…Compared with the two-dimensional structure, the three-dimensional cubic cage structure has a larger cage diameter, but a smaller pore entrance and pore channel, which is more conducive to drug administration [ 26 , 27 , 28 ]. Therefore, it is more meaningful to use SBA-16 as a nano-drug carrier in this study [ 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 ]. However, pH-responsive composites prepared with SBA-16 as the carrier, indoleomycin as the carrier center, and gel polymer as the coating agent have not been reported.…”
Section: Introductionmentioning
confidence: 99%
“…Compared with the two-dimensional structure, the three-dimensional cubic cage structure has a larger cage diameter, but a smaller pore entrance and pore channel, which is more conducive to drug administration [ 26 , 27 , 28 ]. Therefore, it is more meaningful to use SBA-16 as a nano-drug carrier in this study [ 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 ]. However, pH-responsive composites prepared with SBA-16 as the carrier, indoleomycin as the carrier center, and gel polymer as the coating agent have not been reported.…”
Section: Introductionmentioning
confidence: 99%
“…Healthcare-associated infections (HCAIs) are infections that begin 48 h or more after hospitalization or within 30 days after receiving healthcare, and they constitute the second most frequent adverse event suffered by hospitalized patients [ 1 ]. Thus, 5–15% of these patients acquire HCAIs [ 1 ], which represents more than 4 million admitted patients and 7 billion EUR in direct costs per year in Europe [ 2 ]. HCAIs cause prolonged hospitalization, high morbidity and mortality risks, the development of antibiotic-resistant microorganisms, and high costs [ 2 ].…”
Section: Introductionmentioning
confidence: 99%
“…Thus, 5–15% of these patients acquire HCAIs [ 1 ], which represents more than 4 million admitted patients and 7 billion EUR in direct costs per year in Europe [ 2 ]. HCAIs cause prolonged hospitalization, high morbidity and mortality risks, the development of antibiotic-resistant microorganisms, and high costs [ 2 ]. Therefore, the goal must be to avoid the risk of these adverse events between patients and healthcare workers.…”
Section: Introductionmentioning
confidence: 99%
“…In non-leaching polymers, it is indispensable for an antibacterial effect that the bacteria come very close to the surface, but their effect is not exhausted. The field of such contact-killing antimicrobial polymer surfaces has been extensively reviewed [33][34][35][36][37][38]. Among the antimicrobial polymers (e.g., halamines, poly lysine, poly guanidine, quaternary nitrogen groups, antimicrobial peptides [39]), quaternary ammonium compounds (QAC) are probably the most widely used and studied compounds [40,41].…”
Section: Introductionmentioning
confidence: 99%